Correlates of virological non-suppression among children and adolescents aged 5–19 years on Dolutegravir-based regimens attending Gulu regional referral hospital, Northern Uganda: a mixed methods cross-sectional study

The prevalence of virological non-suppression among children and adolescents aged 5-19 years on Dolutegravir-based regimens was 12.2%. This was relatively lower in comparison to other studies conducted in Uganda and other Sub-Saharan African countries but short of the UNAIDS third 95% target for viral suppression.